Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran war drives global fertilizer prices up, raising food cost fears - 2Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- 3A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- 4Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- 5Home Security Frameworks with Shrewd Elements
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Blood pressure drug recalled for possible cross-contamination
- NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
- The Way to Monetary Freedom: A Viable Aide
- Journalist reported killed in the Gaza Strip
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
